Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOX1 | Q9Y5S8 | 8/20 | 0.47 |
| ▸ | GGT1 | P19440 | 5/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.45 |
| ▸ | SNCA | P37840 | 2/20 | 0.45 |
| ▸ | CYBB | P04839 | 1/20 | 0.45 |
| ▸ | APP | P05067 | 1/20 | 0.45 |
| ▸ | NOX3 | Q9HBY0 | 1/20 | 0.45 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5411776 | 0.89 | ALOX5 (0.57) | NOX1GGT1ALOX5GAAMEN1 | |
| SCHEMBL1856711 | 0.83 | NOX1 (0.47) | NOX1GGT1GAAMEN1MAPT | |
| SCHEMBL1509895 | 0.82 | NOX1 (0.46) | NOX1GGT1GAAMEN1MAPT | |
| SCHEMBL1855583 | 0.77 | NOX1 (0.46) | NOX1GGT1GAAMEN1MAPT | |
| SCHEMBL4626664 | 0.77 | NOX1 (0.48) | NOX1GGT1ALOX5GAAMEN1 | |
| SCHEMBL105775 | 0.76 | NOX1 (0.53) | NOX1GGT1GAAMEN1MAPT | |
| SCHEMBL29242179 | 0.75 | NOX1 (0.49) | NOX1GGT1ALOX5GAAMEN1 | |
| SCHEMBL4904429 | 0.74 | NOX1 (0.56) | NOX1GGT1GAAMEN1MAPT | |
| SCHEMBL1509731 | 0.74 | NOX1 (0.47) | NOX1GGT1GAAMEN1MAPT | |
| SCHEMBL31730317 | 0.74 | NOX1 (0.48) | NOX1GGT1GAAMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1317454-B1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMA (US) | 2011-05-25 | — | — | EP | disclosed |
| US-6800619-B2 | UREA HETEROCYCLICCARBONYL-SUBSTITUTED ASPARTIC OR GLUTAMIC ACID DERIVATIVES | VERTEX PHARMACEUTICALS INCORPORATED | 2004-10-05 | — | — | US | disclosed |
| EP-1317454-A2 | CASPASE INHIBITORS AND USES THEREOF | Vertex Pharmaceuticals Incorporated (US) | 2003-06-11 | — | — | EP | disclosed |
| US-20020058630-A1 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2002-05-16 | — | — | US | disclosed |
| WO-2002022611-A2 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058630-A1 | Caspase inhibitors and uses thereof | CASP2, CASP3, CASP7 | NOX1 2272/4885GGT1 802/4885ALOX5 1575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.